Dr. Shin Mukai, PhD is a highly
accomplished chemical biologist with
over 20 years of experience in the
field. He received his Bachelor's
degree in Chemistry from Kyoto
University, followed by a Master's
degree and PhD in Bio-Organic
Chemistry from Kyoto University and
the University of Western Australia,
respectively. After completing his
education, Dr. Mukai worked as a
Postdoctoral Research Fellow at Keio
University School of Medicine and
Brigham and Women's Hospital / Harvard
Medical School. During this time, he
conducted groundbreaking research in
the areas of drug discovery and
development, focusing on novel
treatments for various diseases. In
2022, Dr. Mukai joined Sanofi as a
Scientist III, where he continued his
research in drug discovery and
development. He opened a new avenue
for biology in human B-cells,
eosinophills, neutrophils and mast
cells, making significant
contributions to the field. In 2023,
Dr. Mukai co-founded New Wind
Therapeutics L3C, a pharmaceutical
company that focuses on discovering
and developing new small-molecule
drugs for the treatment of pancreatic
cancer. As the Chief Executive Officer
and Chief Scientific Officer, he
oversees the company's research and
development efforts, utilizing his
extensive knowledge and expertise in
organic/medicinal chemistry, biology
and immunology. Dr. Mukai has
published numerous research papers in
top scientific journals and has
received several awards and honors for
his work. He is highly respected in
the scientific community and continues
to make significant contributions to
the field of chemical biology.